Contact
searchSearch
HMP Global
Login
Test Your Knowledge

Quiz: Which Bladder Cancer Type Shows Elevated Concentrations of 20S Proteasome?

10/28/2021

Recent News

News
Anbenitamab Demonstrates Significant Neoadjuvant Benefit in HER2-Positive Breast Cancer
05/30/2026
Stephanie Holland
Results from a phase 3 trial demonstrated that anbenitamab plus chemotherapy significantly improved total pCR compared with standard neoadjuvant HER2-directed therapy in HER2-positive early or locally advanced breast cancer.
Results from a phase 3 trial demonstrated that anbenitamab plus chemotherapy significantly improved total pCR compared with standard neoadjuvant HER2-directed therapy in HER2-positive early or locally advanced breast cancer.
Results from a phase 3 trial...
05/30/2026
Oncology
News
Erlotinib Plus Ramucirumab Followed by Osimertinib Fails to Extend Time to Failure in EGFR-Mutated NSCLC
05/30/2026
Emily Estrada
Results from the phase 3 REVOL858R trial demonstrated that erlotinib plus ramucirumab followed by osimertinib did not improve outcomes in patients with EGFR-mutated advanced NSCLC.
Results from the phase 3 REVOL858R trial demonstrated that erlotinib plus ramucirumab followed by osimertinib did not improve outcomes in patients with EGFR-mutated advanced NSCLC.
Results from the phase 3...
05/30/2026
Oncology
News
Osimertinib Plus Chemotherapy Extends PFS in Molecularly High-Risk EGFR-Mutated NSCLC
05/30/2026
Emily Estrada
Results from the phase 2 FLAME study demonstrate that osimertinib plus chemotherapy significantly improves PFS in patients with EGFR-mutated advanced non-small cell lung cancer who remain ctDNA-positive after 3 weeks of first-line osimertinib.
Results from the phase 2 FLAME study demonstrate that osimertinib plus chemotherapy significantly improves PFS in patients with EGFR-mutated advanced non-small cell lung cancer who remain ctDNA-positive after 3 weeks of first-line osimertinib.
Results from the phase 2 FLAME...
05/30/2026
Oncology
News
Durvalumab Monotherapy Fails to Significantly Improve DFS in Intermediate-/High-Risk Renal Cell Carcinoma
05/30/2026
Stephanie Holland
Results from the phase 3 RAMPART trial demonstrated that adjuvant durvalumab did not significantly improve DFS compared in intermediate- or high-risk renal cell carcinoma.
Results from the phase 3 RAMPART trial demonstrated that adjuvant durvalumab did not significantly improve DFS compared in intermediate- or high-risk renal cell carcinoma.
Results from the phase 3 RAMPART...
05/30/2026
Oncology
News
Mezigdomide Plus Carfilzomib and Dexamethasone in Heavily Pretreated Patients With R/R Multiple Myeloma
05/29/2026
Stephanie Holland
Results from the phase 3 SUCCESSOR-2 trial demonstrated that mezigdomide plus carfilzomib and dexamethasone significantly improved PFS in previously treated R/R multiple myeloma.
Results from the phase 3 SUCCESSOR-2 trial demonstrated that mezigdomide plus carfilzomib and dexamethasone significantly improved PFS in previously treated R/R multiple myeloma.
Results from the phase 3...
05/29/2026
Oncology
News
Chiauranib Plus Weekly Paclitaxel Significantly Improves PFS in Platinum-Resistant Ovarian Cancer
05/29/2026
Emily Estrada
Results from the phase 3 CHIPRO trial demonstrated that chiauranib plus weekly paclitaxel significantly improved progression-free survival with manageable safety in platinum-resistant or refractory ovarian cancer.
Results from the phase 3 CHIPRO trial demonstrated that chiauranib plus weekly paclitaxel significantly improved progression-free survival with manageable safety in platinum-resistant or refractory ovarian cancer.
Results from the phase 3 CHIPRO...
05/29/2026
Oncology
News
Sunvozertinib Significantly Improves PFS in EGFR-Mutated Non-Small Cell Lung Cancer
05/29/2026
Stephanie Holland
Results from the phase 3 WU-KONG28 trial demonstrated that sunvozertinib significantly improved PFS in previously untreated patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertion mutations.
Results from the phase 3 WU-KONG28 trial demonstrated that sunvozertinib significantly improved PFS in previously untreated patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertion mutations.
Results from the phase 3...
05/29/2026
Oncology
FDA Approval
FDA Approves Durvalumab Plus BCG for BCG-Naïve Patients With Non-Muscle Invasive Bladder Cancer
05/28/2026
Stephanie Holland
Based on results from the phase 3 POTOMAC study, the FDA has approved durvlaumab plus Bacillus Calmette-Guerin (BCG) for BCG-naïve patients with high-risk non-muscle invasive bladder cancer.
Based on results from the phase 3 POTOMAC study, the FDA has approved durvlaumab plus Bacillus Calmette-Guerin (BCG) for BCG-naïve patients with high-risk non-muscle invasive bladder cancer.
Based on results from the phase...
05/28/2026
Oncology
FDA Approval
FDA Approves Pivekimab Sunirine for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasms
05/27/2026
Emily Estrada
Based on results from the phase 2 CADENZA trial, the FDA has approved pivekimab sunirine for adult patients with blastic plasmacytoid dendritic cell neoplasms.
Based on results from the phase 2 CADENZA trial, the FDA has approved pivekimab sunirine for adult patients with blastic plasmacytoid dendritic cell neoplasms.
Based on results from the phase...
05/27/2026
Oncology
News
Lorlatinib Maintains Long-Term Benefit in Advanced ALK-Positive Non-Small Cell Lung Cancer
05/27/2026
Emily Estrada
Updated results from the phase 3 CROWN study demonstrate that lorlatinib sustains long-term benefit in treatment-naïve patients with advanced ALK-positive non-small cell lung cancer.
Updated results from the phase 3 CROWN study demonstrate that lorlatinib sustains long-term benefit in treatment-naïve patients with advanced ALK-positive non-small cell lung cancer.
Updated results from the phase 3...
05/27/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use